Fyodor Biotechnologies Inc. announced on August 16 it has expanded its office and laboratory space at the University of Maryland BioPark in Baltimore, moving from the BioPark’s BioInnovation Center (BIC) at 801 West Baltimore Street to the expanded BioInnovation Center across the street at 800 West Baltimore Street. The move is prompted by Fyodor’s advancing research and development activities, including those related to its urine-based malaria diagnostic assay.
“The timing of the move is critical for us as Fyodor prepares to broaden its research and development activities,” Eddy Agbo, D.V.M., Ph.D., chairman and CEO of Fyodor Biotechnologies, said. “The advantages to us of being located within the University of Maryland BioPark go beyond the tangible amenities such as access to core facilities. The BioPark also provides us the opportunity to interact at a number of levels with other life science organizations at varying stages of development, providing valuable insight and experience.”
Fyodor joins InstantLabs, PathSensors and GSSHealth in the 800 West Baltimore BIC. Newly-renovated, pre-built wet lab and office suites on the fourth floor of the Park’s first commercial building include flexible lease terms for emerging bioscience companies that have grown from initially leased space within the BIC at 801 West Baltimore Street or from early incubator space at other locations.
“Fyodor is an important member of the growing BioPark family of companies. It’s rewarding for us to provide an environment that helps to foster the company’s continued R&D advancement,” Jane Shaab, BioPark executive director said.
About Fyodor Biotechnologies, Inc.
Founded in 2008, Fyodor Biotechnologies is focused on the research, development and manufacture of innovative diagnostic and biopharmaceutical products targeted to global health diseases. We identify novel biotechnologies that have compelling relevance to global health diseases and translate them into tangible simple-to-use products. Fyodor’s flagship product is the Urine Malaria Test – a one-step test for at-home or point-of-need diagnosis of clinical malaria in persons with fever. About Malaria According to the World Health Organization’s World Malaria Report 2011, half of the world’s population is at risk of malaria, and an estimated 216 million cases lead to over 655,000 deaths annually, the majority of deaths in children under the age of five. The U.S. Department of Commerce reports that about 18 million U.S. travelers visited countries affected by malaria in 2008. In addition, malaria continues to be a concern to U.S. military deployed to malaria-endemic regions.
About the University of Maryland BioPark
The UM BioPark is a biomedical research park on the campus of the University of Maryland, Baltimore. The BioPark welcomes additional life science companies to join its growing scientific community of emerging, high-growth life science tenants and University of Maryland (UM) translational research and clinical treatment centers. For early-stage to mature bioscience companies, the BioPark offers a sophisticated laboratory and office environment on the UM’s vibrant academic medical center campus. Community members are commercializing new drugs, diagnostics and devices and advancing biomedical research.